| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jul 8, 2011Update to July 2009 Letter to Healthcare Professionals
MINNEAPOLIS, Jul 08, 2011 (BUSINESS WIRE) -- As part of its ongoing commitment to keep patients and physicians informed about product performance and safety, Medtronic, Inc. (NYSE: MDT) is issuing...
-
May 5, 2011New Leads Add to Company's Expansive Portfolio of Innovative CRT-Related Technology Proven to Treat Heart Failure Patients
MINNEAPOLIS & SAN FRANCISCO, May 05, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA) approval and launch of the Attain Ability(R)...
-
May 3, 2011New Feature Set Includes External AC/DC Power and Temperature Monitoring for Therapeutic Hypothermia Patients
REDMOND, Wash., May 03, 2011 (BUSINESS WIRE) -- Physio-Control, Inc., a global leader in emergency medical solutions and wholly-owned subsidiary of Medtronic, Inc. (NYSE: MDT), today announced...
-
Apr 27, 2011Shareholders Invited to Attend Annual Meeting on Aug. 25, 2011
MINNEAPOLIS, Apr 27, 2011 (BUSINESS WIRE) -- The board of directors of Medtronic, Inc. (NYSE: MDT), today announced that the company's annual meeting of shareholders will be held at 10:30 a.m.,...
-
Mar 28, 2011Late-Breaking Clinical Trials Feature One-Year Results of RESOLUTE US Study; Latest Evidence from Comprehensive Research Program Completes FDA Approval Submission
MINNEAPOLIS, Mar 28, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT), today announced the imminent release of the pivotal U.S. data on its Resolute(R) drug-eluting stent (DES) at ACC.11, the 60th